Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ongericimab + toripalimab + bevacizumab + FOLFOX
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy is being evaluated in the Phase II ONTOP clinical trial for the treatment of advanced microsatellite stable (MSS) or proficient mismatch repair (pMMR) colorectal cancer. The regimen consists of **ongericimab** (JS002), a monoclonal antibody targeting PCSK9; **toripalimab** (JS001), a monoclonal antibody targeting the PD-1 receptor; **bevacizumab**, an anti-VEGF monoclonal antibody; and the **FOLFOX** chemotherapy regimen (oxaliplatin, calcium folinate, and 5-fluorouracil). The study, sponsored by Shanghai Pudong Hospital, investigates whether the addition of a PCSK9 inhibitor can overcome the typical resistance of MSS/pMMR colorectal tumors to immune checkpoint inhibitors by modulating the tumor microenvironment and enhancing MHC-I expression.
- Brand names
- Tuoyi
- Other names
- JS002 + JS001 + bevacizumab + FOLFOX
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)DNA
Beyond the preview
Go deeper on ongericimab + toripalimab + bevacizumab + FOLFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ongericimab + toripalimab + bevacizumab + FOLFOX.